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Abstract
Background: The CGRP antagonists offer a novel therapeutic approach in migraine. Their utility in patients with
severe forms of chronic migraine is a subject of particular interest. We present outcomes of 9 months of erenumab
treatment in a cohort of patients with difficult-to-control chronic migraine, all of whom had prior unsatisfactory
response to onabotulinumtoxinA.
Methods: We offered erenumab to 98 patients with a prior unsatisfactory response to onabotulinumtoxinA. Eighty
of 98 had trialled greater occipital nerve injections (82%), 32/98 peripheral neurostimulation (33%) and 18/98
intravenous dihydroergotamine (18%). Thirty eight of 98 (39%) met the definition of triptan overuse and 43/98
(44%) analgesic overuse. All patients met the EHF criteria for ‘resistant migraine’. Outcome measures (recorded
monthly) included days with headache limiting activities of daily living (“red”), not limiting (“amber”), headache free
(“green”), and requiring triptans or other analgesics. Quality of life scores - headache impact test 6 (HIT-6), patient
health questionnaire 9 (PHQ-9) and pain disability index (PDI) - were also measured.
Results: Mean number of red days improved by − 6.4 days (SE 0.67, 95%CI − 7.7 to − 5.1, p=0.001) at 3 months; −
6.8 days (SE 0.96, 95%CI − 8.80 to − 4.9, p=0.001) at 6 months and − 6.5 days (SE 0.86, 95%CI − 8.3 to − 4.8, p=0.001)
at 9 months. Repeated measures ANOVA confirmed improvements in the number of red (p=0.001), green (p=0.001),
triptan (p=0.001) and painkiller days (p=0.001) as well as scores of the HIT-6 (p=0.001), PHQ-9 (p=0.001), and PDI (p=
0.001) across the duration of study.
Conclusion: We observed improvements in pain, medication use and quality of life in onabotulinumtoxinA-
resistant chronic migraine patients following erenumab treatment.
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Background
The calcitonin gene-related peptide (CGRP) monoclonal
antibodies offer a novel therapeutic approach to mi-
graine. Their efficacy has been demonstrated in clinical
trials of both acute and chronic migraine [1–10]. In
2017, a randomised controlled trial of erenumab in
chronic migraine demonstrated a reduction of between
− 1.4 and − 3.5 migraine days at 9 to 12 weeks compared
to placebo [8]. In 2018, erenumab was approved by both
the US Food and Drug Administration (FDA) and the
European Medicines Agency (EMA) for episodic mi-
graine and chronic migraine in adults who have at least
4 migraine days per month.
Emerging real-world data suggests that erenumab can
be effective in patients with more severe migraine phe-
notypes, including those with a history of treatment fail-
ure [11–23]. Its utility in patients with a prior
unsatisfactory response to onabotulinum toxinA
(BoNTA), is of particular interest. In view of the rela-
tively higher cost of this treatment compared to oral
preventatives and its requirement to be administered in
a clinic by trained healthcare providers, it is generally re-
served for patients with more severe forms of migraine.
The emergence of CGRP antagonists as a novel mi-
graine treatment has created considerable interest
amongst clinicians, however associated costs of treat-
ments currently limit their use in clinical practice. In
England, for example, erenumab is deemed not to be
cost effective within its marketing authorisation, and re-
mains unavailable for patients. A recent appeal against
this decision upheld that the National Institute of Clin-
ical Excellence (NICE) had failed to consider the poten-
tial benefit of erenumab specifically in one group of
patients; those that had failed to benefit from BoNTA or
when it is contra-indicated (https://www.nice.org.uk/
guidance/gid-ta10302/documents/appeal-decision).
In view of this, we present our outcomes of erenumab
treatment (provided under a commercial supply agree-
ment) in an open-label audit of patients with chronic
migraine, all of whom had a prior unsatisfactory re-
sponse to BoNTA.
Methods
The study was designed and conducted by the neurology
department at Derriford Hospital, Plymouth, a large ter-
tiary referral centre for headache treatment in Devon
and Cornwall, United Kingdom. It was registered locally
as an audit, which under current national guidelines
does not require research ethics committee review
(http://www.hra-decisiontools.org.uk/research/).
Participants and setting
Between February 2019 and July 2020 erenumab was
offered to patients who met the International
Classification of Headache Disorders (ICHD) definition
of chronic migraine. All had previously had an unsatis-
factory response to BoNTA (≤30% reduction in head-
ache days following two treatments and/or lack of
tolerability) and had failed and/or had contraindications
to ≥2 classes of preventative medications. Patients with
medication overuse were included. Patients receiving
oral prophylactic medications were allowed to continue
this during the study. No patient received BoNTA con-
currently with erenumab.
Invitation letters were sent to patients deemed eligible:
Responders were booked into an information session
conducted by the headache specialist nurse (RS) sup-
ported by the headache assistant (LC). During this ses-
sion patients received verbal and written information
about the medication, training in self-administration of
subcutaneous injections, further instruction in how to
fill out the headache diaries and were individually con-
sented and signed a written consent form. This specified
the possibility that the drug might be stopped following
discontinuation of the ‘free of charge scheme’ and that
data would be collected in order to determine their
treatment response.
Erenumab was provided free of charge by Novartis
(The Westworks, 195 Wood Lane, London, W12 7FQ)
through a commercial supply agreement. The drug was
delivered directly to participants. Participants were free
to discontinue at any point. In order to objectively docu-
ment treatment response, data relating to the number of
headaches pre and post treatment as well as effect on
quality of life was collected. They received telephone
follow-up via the unit headache nurse (RS) at 2 months
to document side effects and assess treatment response
and at 3 monthly intervals thereafter.
All patients started on a dose of 70 mg, self-injecting
monthly. At the first telephone follow up, patients were
offered a dose increase from 70mg to 140 mg unless
they were experiencing side effects deemed to be related
to erenumab and which contraindicated such an in-
crease. Those who did not receive a dose escalation at 2
months were reassessed at each subsequent follow up
and were offered a dose increase if appropriate.
Outcome measures
Patients were asked to record a standardised (handwrit-
ten) headache diary. A traffic light scoring system of the
number of ‘red’, ‘amber’ and ‘green’ days was used to
grade headache severity. Red days represented days with
headaches which limited activities of daily living or
which required use of triptans, amber days represented
days with headaches but no limitation to activities of
daily living, and green days represented headache-free
days. Patients also completed standardised, validated
scores of various functional domains – patient health
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questionnaire 9 (PHQ-9) [24], headache impact test 6
(HIT-6) [25, 26] and pain disability index (PDI) [27], and
recorded the number of days requiring triptans and re-
quiring other painkillers (simple and/or opiate-based).
All data was returned monthly via post or email.
Statistics
Graphs and statistical analyses were performed on Stata
version 14.0 (4905 Lakeway Drive, Texas, 77,845, USA).
We examined the different reasons for discontinuing
treatment by performing a sensitivity analysis. It revealed
an association between discontinuation of erenumab and
a poor treatment response/side effects. This meant that
data was deemed to be not missing at random, and
therefore imputation or other adjustment strategies
would not be appropriate.
The normality of the distribution of the change in
number of red days was assessed by visual inspection (q
plots available in supplementary materials). As such,
parametric analyses were deemed appropriate. A two
tailed paired t-test was performed to assess the change
in the number of red headache days from baseline
(month 2) reported at 3 months, 6 months and 9months
from the commencement of treatment. A repeated mea-
sures ANOVA was used to assess the change in all
scores across the 12 months of data collection.
We modelled the potential impact of missing data. We
assumed that in those where missing data was present,
there was a 10 day increase in the number of red days
from baseline. Accordingly all missing values were set at
+ 10 red days from the baseline value (month 2). We
reassessed the normality of these distributions and found
they were non-parametric; we therefore repeated our re-
peated measures analysis using Friedman’s test and our
cross sectional analyses using a Wilcoxon signed rank
test.
A Bonferroni correction for multiple comparisons (fac-
tor of 11) was performed on all analyses.
Results
Participants
A flow chart of recruitment is available in Fig. 1. One
hundred and twenty five patients were sent invitation
letters. Nineteen patients did not attend the training day
or opted out prior to their first injection. A total of 106
patients received at least one dose of erenumab. Of
these, 8 patients did not submit a single month of either
pre- or post-treatment data and were not included in
data analysis. Seven of 8 (88%) had no response to treat-
ment, two of whom experienced side effects. In total
data from 98 patients were analysed. Fifty six patients of
these 98 (57%) underwent a dose increase to 140 mg at a
median of 2 (IQR 1) months after treatment initiation.
A summary table of demographics at baseline are
displayed in Table 1. Eighty one out of 98 (83%) par-
ticipants were female. The mean age at enrolment
was 50.4 (SD 12.4) years. Subjects had suffered with
migraine for a mean of 19.6 years (SD 13.0). Of the
98 participants, 92/98 (94%) suffered ‘a severe impact’
from their headaches as determined by a HIT-6 score
≥60 [25], 81/98 (83%) had concurrent depression
(PHQ-9 score ≥10) [24], 38/98 (39%) met the defin-
ition of triptan overuse (≥10 days/month) and 43/98
(44%) met the definition of analgesic overuse (≥15
days/month). All patients met the definition of ‘resist-
ant migraine’ as defined by the recent European
Headache Federation (EHF) consensus. As this was
the first trial of a CGRP inhibitor in all our patients,
none met the definition of ‘refractory migraine’, which
stipulates a failed trial of this medication class [28].
All patients had undergone treatment with BoNTA
but had not achieved a clinically relevant response
(≥30% improvement in headache days according to
headache diaries/clinical assessment). Of the 98 pa-
tients, 80/98 (82%) had received a trial of greater oc-
cipital nerve injections, 18/98 (18%) had received a
trial of intravenous dihydroergotamine and 32/98
(33%) had received a trial of a peripheral neurostimu-
lation device.
We also quantified previous use of migraine-specific
oral preventives, for which comprehensive information
was available in 92/98 (94%) patients. The mean
number of trialled migraine-specific oral preventives
(including medications within the same class) in these
patients was 5.5 (SD 1.8), which included beta-
blockers (propranolol, atenolol; 68/92 patients, 74%),
tricyclics (amitriptyline and nortriptyline; 80/92 pa-
tients, 87%), anticonvulsants (topiramate, gabapentin,
pregabalin and sodium valproate; 83/92 patients,
90%), angiotensin II receptor blockers (candesartan;
47/92 patients, 51%), calcium channels blockers (flu-
narizine; 16/92 patients, 17%), serotonin antagonists
(pizotifen; 39/92 patients, 42%), and anti-depressants
(venlafaxine, mirtazapine, duloxetine; 8/92 patients,
9%).
Safety, tolerability and missing data
A flow chart of study recruitment and retention is
provided in Fig. 1. A table of missing data and rea-
sons for this are included in Table 2. A total of 24/98
(24%) patients opted to discontinue erenumab during
the study period: Eighteen of 98 (18%) patients chose
to discontinue due to a perceived lack of benefit, and
a further 5/98 (5%) discontinued due to one or more
side effect(s), namely rash (1/98), palpitations (1/98),
gastrointestinal upset (2/98), tightness in throat (1/
98), and hypertension (1/98). One patient (1/98)
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became pregnant during treatment resulting in dis-
continuation of the drug. Forty-two of the 98 partici-
pants (43%) had not completed 9 months of
treatment at the time of data analysis, but continued
to take and tolerate erenumab.
Outcomes
A table of outcomes across the period of data collection
are provided in Table 3.
Effect on headache days
There were sustained reductions in the mean number of
red days per month across the study period (repeated
measures ANOVA, p=0.001, Fig. 3). There was a mean
of 15.7 (SD 8.2) red days/month at baseline. Following
treatment there were improvements in monthly red days
of − 6.4 days (SE 0.67, 95%CI − 7.7 to − 5.1, t=9.6, p=
0.001, Fig. 2) at 3 months; − 6.8 days (SE 0.96, 95%CI −
8.8 to − 4.9, t=7.0, p=0.001), Fig. 2) at 6 months and −
6.5 days (SE 0.86, 95%CI − 8.3 to − 4.8, t=7.6, p=0.001,
Fig. 2) at 9 months. Respectively 71/98 (72%), 42/50
(84%) and 25/27 (93%) experienced a reduction in the
number of red days at 3, 6 and 9 months respectively.
Fifty three of 90 (59%), 31/50 (62%) and 16/27 (59%) ex-
perienced at least a 5 day improvement (reduction) in
the number of red days at 3, 6 and 9 months.
There was a mean of 3.6 (SD 5.4) green days/month at
baseline. Following treatment there were improvements
in the mean number of green days/month (repeated
measures ANOVA p=0.001, Fig. 3). There were + 5.7
days (SE 0.8, SD 7.6) at 3 months, + 6.9 days (SE 1.1, SD
Table 1 Demographic factors in patients receiving erenumab
Participant characteristics
%female 81/98 (82.7%)
Mean age, SD (range) 50.4, 12.4
(18–75)
Mean, SD (range) number of years with migraine 19.6, 13 (3–
58)
Mean, SD (range) number of trialled migraine-specific
oral preventive drugs
5.5, 1.8 (1–9)
Previous trial of greater occipital nerve injections 80/98 (81.6%)
Previous trial of intravenous dihydroergotamine 18/98 (18.4%)
Previous trial of peripheral neurostimulation device 32/98 (32.7%)
Depression (based on PHQ-9 score >=10) 81/98 (82.7%)
Severe impact of headaches (HIT-6 >=60) 92/98 (93.8%)
Triptan overuse (>= 10 days/month) 38/98 (38.8%)
Other analgesic overuse (>=15 days/month) 43/98 (43.9%)
‘Resistant migraine’ by EHF criteria 98/98 (100%)
Fig. 1 Audit design flowchart. 125 patients who met the ICHD definition of chronic migraine, had failed and/or had contraindications to ≥2
classes of preventative medications, and had a previous unsatisfactory response to BoNTA were selected for the audit. 19 patients did not attend
the training day or opted out of the audit prior to the first injection. A total of 106 patients received at least one dose of erenumab. 8 patients
who did not submit at least one month of pre- or post-treatment data were excluded from the analysis
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Table 2 Table of missing data
Month of study no treatment baseline treatment
0 1 2 3 4 5 6 7 8 9 10 11
Total number of patients included in analysis 71 93 98 97 90 86 83 72 50 45 31 27
Data not submitted 27 5 0 1 0 0 0 0 3 3 5 3
Ineffective (cumulative) 0 0 0 0 3 6 8 11 17 18 18 18
Side effects (cumulative) 0 0 0 0 3 4 4 5 5 5 5 5
Other reason (cumulative) 0 0 0 0 0 0 0 0 0 0 0 1
Ongoing treatment at time of analysis (cumulative) 0 0 0 0 2 2 3 10 23 27 39 44
Table accounting for missing data throughout the study period. Three months of baseline data (month 0, 1, 2) is followed by nine months of post-treatment data
(month 3–11), when patients received monthly erenumab injections. The total number of patients included in the dataset for each month is shown at the top.
This is broken down into the number of patients who failed to submit a questionnaire for each given month but remained in the analysis (‘data not submitted’),
and cumulative discontinuation rates throughout the study period for various reasons (ineffectiveness, side effects, other (specifically, pregnancy). The final
column shows the cumulative number of patients that were continuing to receive erenumab but had not completed sufficient months of treatment to provide
data beyond a certain timepoint
Table 3 Outcomes across the duration of the study
Month Pre-treatment Baseline Post- treatment ANOVA










































































































































































































































































t value 9.6 7.0 7.6
Corrected p=0.001 p=0.001 p=0.001




Values are mean (SE, SD)
Raw data for all outcomes. 98 patients received at least one dose of erenumab and were analysed. Three months of pre-treatment data were collected, with
month 2 used as baseline. Outcomes are recorded up to nine months of treatment (month 11), and relate to the mean number of red days (headache limiting
activities of daily living), amber days (headache but no limitation to activities of daily living), green days (headache-free), triptan days (requiring use of one or
more triptans), painkiller days (requiring use of simple and/or opiate analgesics), HIT-6 (headache impact test-6) score, PHQ-9 (patient health questionnaire-9)
score, and PDI (pain disability index) score. Analysis of variance p values are shown for each outcome, both corrected following Bonferroni calculation for multiple
comparisons, and uncorrected. Below, t tests comparing mean scores relating to the change in number of red days per patient at month 5, 8 and 11 (three, six
and nine months post-treatment, respectively) compared with baseline (month 2) are shown
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7.9) at 6 months and + 7.4 days (SE 1.5, SD 8.0) at 9
months. Forty six of 86 (53%), 28/50 (56%) and 17/27
(63%) respectively experienced some improvement in
the number of green days at 3, 6 and 9 months. 36/86
(42%), 28/50 (56%) 15/27 (56%) experienced at least a 5
day improvement in the number green days at 3, 6 and
and 9 months respectively. There was no significant dif-
ference in the number of amber days (repeated measures
ANOVA p=1.0, Fig. 3).
Effect on triptan and other painkiller use
There were significant improvements in the mean
number of days requiring triptans (repeated measures
ANOVA, p=0.001, Fig. 4) and other painkillers (re-
peated measures ANOVA, p=0.001, Fig. 4). The
change from baseline of mean number of days requir-
ing triptans per month was − 3.4 days (SE 0.6, SD 6.0)
at 3 months, − 3.9 days at 6 months (SE 0.9, SD 6.3)
and − 3.9 (SE 1.0, SD 5.2) at 9 months. The mean
number of painkiller days per month changed from
baseline by − 2.2 days (SD 6.7) at 3 months, − 3.2 days
(SD 7.9) at 6 months and − 3.9 days (SD 7.6) at 9
months. Of the patients who completed six months of
treatment/assessments, 23/50 (46%) met the definition
of triptan overuse (≥10 days/month) and 20/50 (40%)
of analgesia overuse (≥15/month) at baseline. At 6
months 5/50 (10%) and 11/50 (22%) met the defin-
ition of triptan and analgesia overuse respectively.
Effect on quality of life measures
There were clinically meaningful [29–31] statistically sig-
nificant improvements in the PHQ-9 (repeated measures
ANOVA: p=0.001, Fig. 5), HIT-6 (repeated measures
ANOVA: p=0.001, Fig. 5) and PDI (repeated measures
ANOVA: p=0.001, Fig. 5). From baseline mean change
in PHQ-9 score was − 5.2 (SE 0.62, SD 5.6) at 3 months,
− 6.0 (SE 1.0, SD 7.1) at 6 months and − 7.2 (SE 1.1, SD
5.8) at 9 months. Mean change in HIT-6 score was − 7.1
(SE 1.1, SD 10.5) at 3 months, − 9.0 (SE 1.2, SD 8.7) at 6
months and − 10.9 (SE 1.8, SD 9.0) at 9 months. Mean
change in PDI score was − 12.1 (SE 1.8, SD 16.0) at 3
months, − 14.6 (SE 1.0, SD 14.6) at 6 months and − 17.9
(SE 3.5, SD 18.0) at 9 months.
Modelling to assess the impact of dropouts on change in
number of red days
Because we were unable compensate for missing data
statistically, we assessed the potential effect of dropouts
using a crude and highly conservative model estimating
the change of red headache days they were experiencing.
Where data was missing, we stipulated that the number
of red headache days increased by 10 days from the base-
line (month 2) value. This meant that our model as-
sumed each participant experienced a 10 day increase in
the number of red days they were experiencing if miss-
ing data was present. Using this model, there was a sig-
nificant change in the number of red days across the 12
months of data collection (Friedman’s test, p=0.001). A
Fig. 2 Box plots with dot plots, showing the number of red headache days/month at baseline (month 2) and 3, 6 and 9months after treatment
initiation (respectively months 5, 8 and 11)
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Fig. 3 Graphs showing change in mean monthly headache days before and after commencing erenumab. Three months of baseline data
(month 0, 1, 2) is followed by 9 months of post-treatment data (month 3–11). Red days signify days with headaches that limit activities of daily
living, amber days signify days with headache but not limiting activities of daily living, and green days signify days free of any headache. Error
bars represent standard error of the mean
Fig. 4 Graphs showing mean number of days requiring triptans, and requiring painkillers (simple or opiate analgesics), before and after
commencing erenumab. Three months of baseline data (month 0, 1, 2) is followed by 9 months of post-treatment data (month 3–11). Error bars
represent standard error of the mean
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significant reduction in the number of red days
remained at 3 months (median change − 5 days, IQR 10,
Wilcoxon rank sign, p=0.001).
Discussion
We present real world findings of erenumab treatment
in ‘hard to treat’ chronic migraine sufferers. Our results
show significant improvements in the number headache
days, medication use and measures of functional per-
formance. We feel the patient group is broadly represen-
tative of patients with difficult to control chronic
migraine which frequently includes co-existing depres-
sion and medication overuse. All patients had an unsat-
isfactory response to BoNTA and had trialled multiple
oral preventatives. A high proportion of patients had
also received other treatment modalities.
The European Headache Federation (EHF) definitions
of resistant and refractory migraine were recently revised
[28]. Resistant migraine has been redefined as failure or
contraindication to at least 3 specified classes of mi-
graine preventatives and suffering from at least 8 debili-
tating headache days per month for at least 3
consecutive months without improvement. Refractory
migraine relates to failure of all of the available preven-
tatives, including BoNTA and a CGRP-modulating drug,
and suffering from at least 8 debilitating headache days
per month for at least 6 consecutive months. All patients
in our cohort met the definition of resistant migraine at
study enrolment.
A substantial majority (84% at 6 months) of our pa-
tient cohort reported a response to erenumab, which
was in most cases relatively rapid. At 3 months post
treatment there was a mean − 6.4 day improvement in
the number of red days (headaches that impacted signifi-
cantly on day-to-day activities) and a + 5.7 day improve-
ment in the number of headache-free (green) days. At 6
months there was a mean − 6.8 day improvement in
monthly red days and a mean improvement (+ 6.9 days)
in the number of green days. Analgesia and triptan over-
use both declined and there were clinically relevant im-
provements on all three measures of quality of life
undertaken. We recorded outcomes up to 9 months in
27 patients. We found, in accordance with other studies
[11, 12, 14, 20, 23], that patients continued to show
Fig. 5 Graphs showing change in mean quality of life scores (PHQ9, HIT-6, and PDI) before and after commencing erenumab. Three months of
baseline data (month 0, 1, 2) is followed by 9 months of post-treatment data (month 3–11). Error bars represent standard error of the mean
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sustained improvements over time, although the max-
imal benefit was seen in the first 4 months. This sug-
gests that sustained trial of erunumab is necessary
before being able to make a true assessment of treat-
ment response.
A number of other studies have examined the effect-
iveness of erenumab in a non-controlled manner. An
Italian study of erenumab in patients with enduring epi-
sodic and chronic migraine with high rates of medica-
tion overuse demonstrated a reduction of 15 migraine
days in 76 patients [11]. Among the 44 patients who had
failed treatment with BoNTA, 31 (70.5%) responded to
the treatment. Giorgio et al. examined erenumab in
treatment-refractory UK migraine sufferers that had
failed ≥3 preventive treatments [12]. The majority had
had an inadequate response to BoNTA and none had
responded to greater occipital nerve blocks. They dem-
onstrated significant reductions in monthly migraine
days of 7.5 days at 6 months. A German study of erenu-
mab in patients that had failed five oral prophylactics
and type A botulinum toxin led to a reduction of 4.7
headache days after three treatment cycles [13]. A num-
ber of other recently published studies have shown simi-
lar improvements with erenumab [14–23], although only
one has examined its benefit exclusively in BoNTA fail-
ures [18]. Our outcomes, recorded up to 9 months, in
general exceed those of other studies [14–18, 23] and do
not rely on retrospective reporting [13, 15, 21, 22], pro-
viding more objective evidence of treatment efficacy.
Our data suggests that erenumab is a safe and well-
tolerated treatment. Only 5/98 (5%) discontinued erenu-
mab due to side effects. This compares to 2.2% [11], 12%
[12] and 4.3% [13] respectively in other comparable
datasets. A large retrospective study of 241 patients
treated with erenumab found an incidence of 70% of at
least one adverse event, the most common being consti-
pation, although most patients felt the benefit of treat-
ment outweighed any drawbacks [21]. One patient in
our cohort developed hypertension as a result of erenu-
mab treatment, a complication noted previously [12],
suggesting there is a need for monitoring of blood pres-
sure in patients treated with erenumab.
Limitations
We observed improvements in multiple outcomes fol-
lowing erenumab treatment, however as a non placebo-
controlled study, it is not possible to infer causality. We
also acknowledge the potential confounding effect of
drop-outs and incomplete data. Our data probably over-
estimates the effect size of erenumab use on account of
attrition bias, caused by preferential drop out of those
who did not respond to the drug or experienced side ef-
fects. This is a limitation which is also a confounder in
other comparable studies [11–13]. That said, our
modelling demonstrates that even in the unlikely sce-
nario that all those who dropped out (or had been
treated for less than 9 months) experienced a 10 day in-
crease in the number of monthly red days from baseline,
significant reductions in the number of red days were
retained. This suggests the confounding effect of attri-
tion bias is unlikely to have resulted in type 1 error (false
positive).
Our categorisation of headache differs to other studies,
in which ‘migraine’ days are specifically defined, for ex-
ample, on the basis of headache duration or a combin-
ation of pain and/or non-pain features. Our traffic light
system was deliberately chosen to enable patients to cat-
egorise the severity and impact of their headache rela-
tively easily, as we hoped this would potentially reduce
subjective variation in reporting.
Post-hoc analysis of data from randomised studies of
erenumab has suggested an advantage of the 140 mg
dose on treatment outcomes, which is more evident in
patients with a higher rate of prior treatment failure
[32]. In our study the criteria for dose escalation was
driven by patient preference, whilst dose increases were
not uniformly undertaken at defined time points. As a
result, the effect of 70 mg vs 140 mg dose in our cohort
cannot be inferred, as this aspect of the dataset is subject
to confounding and bias.
Conclusions
We present our real-world findings of erenumab in a co-
hort of people with chronic migraine, all of whom had
tried and discontinued multiple migraine preventatives
including onabotulinumtoxinA, and who also had a high
prevalence of depression and medication overuse. We
feel our cohort is representative of the small minority of
patients with difficult-to-treat chronic migraine who do
not respond to readily available therapies (ie non-CGRP
treatments). We found significant improvements in
terms of both the number of headache days and their
functional impact. Placebo-controlled trials in this popu-
lation are required to confirm these findings.
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